Company Encyclopedia
View More
name
GUIZHOU SANLI
603439.SH
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China.
3.095 T
603439.SHMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking146/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.42%B
    • Profit Margin9.26%B
    • Gross Margin71.54%A
  • Growth ScoreE
    • Revenue YoY-17.84%E
    • Net Profit YoY-51.14%D
    • Total Assets YoY-6.88%D
    • Net Assets YoY-16.66%E
  • Cash ScoreC
    • Cash Flow Margin1080.25%B
    • OCF YoY-17.84%E
  • Operating ScoreB
    • Turnover0.59B
  • Debt ScoreC
    • Gearing Ratio45.64%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GUIZHOU SANLI: Yuexin Pharmaceutical reduced its holdings by 0.1976%

    GUIZHOU SANLI announced that the shareholding reduction plan of Hainan Yuexin Pharmaceutical Investment Partnership, a shareholder holding more than 5%, has expired. From July 3, 2025, to October 2, 2025, it will reduce its holdings by 809,900 shares through centralized bidding, accounting for 0.1976% of the company's total share capital; after the reduction, it will hold 20,190,100 shares, accounting for 4.9268%. The previous plan was to reduce no more than 2,049,000 shares, accounting for 0.5000%

    Zhitong·
    SH
    603439
    -1.26%
    Zhitong·
    SH
    603439
    -1.26%

    GUIZHOU SANLI: Completed the repurchase of 7.8693 million shares

    GUIZHOU SANLI announced that the company will complete its share repurchase from September 13, 2024, to September 12, 2025. The actual number of shares repurchased is 7.8693 million shares, accounting for 1.92% of the total share capital, with a repurchase amount of 99.9544 million yuan, and a price range of 11.82 yuan/share to 14.2 yuan/share. The repurchased shares will be used for the employee stock ownership plan or equity incentive plan

    Zhitong·
    SH
    603439
    -1.26%
    Zhitong·
    SH
    603439
    -1.26%

    GUIZHOU SANLI: Net profit in the first half of 2025 decreased by 29.04% year-on-year

    GUIZHOU SANLI announced that in the first half of 2025, operating revenue was 702 million yuan, a year-on-year decrease of 23.73%. Net profit was 83.061 million yuan, a year-on-year decrease of 29.04%. Basic earnings per share were 0.20 yuan/share, a year-on-year decrease of 31.03%

    Zhitong·
    SH
    603439
    -1.26%
    Zhitong·
    SH
    603439
    -1.26%

    GUIZHOU SANLI plans to sign a technology transfer contract and a technology development (cooperation) contract with Guangdong Pharmaceutical University

    GUIZHOU SANLI plans to sign technology transfer and technology development contracts with Guangdong Pharmaceutical University, aiming to integrate the company's industrialization capabilities with university research and development resources, promote the transformation of innovative drug research results, and enhance market competitiveness. This cooperation aligns with the company's long-term development strategy and is expected to have no significant impact on this year's financial situation, but the impact on future operating performance will depend on the progress of project implementation

    Zhitong·
    SH
    603439
    -1.26%
    Zhitong·
    SH
    603439
    -1.26%

    Some shareholders, directors, and executives of GUIZHOU SANLI plan to reduce their holdings in the company

    According to the Zhitong Finance APP, GUIZHOU SANLI announced that the company recently received a "Share Reduction Plan Notification Letter" from shareholders holding more than 5% of the shares, including Hainan Yuexin Pharmaceutical Investment Partnership (General Partnership); Vice Chairman, General Manager, and Board Secretary Zhang Qianfan; Director and Deputy General Manager Wang Yi; Deputy General Manager Yu Yuan; and Deputy General Manager Luo Zhanbiao. The above shareholders plan to collectively reduce their holdings by no more than 2.6664 million shares of the company

    Zhitong·
    SH
    603439
    -1.26%
    Zhitong·
    SH
    603439
    -1.26%
    © 2025 Longbridge｜Disclaimer